Bon Secours Cancer Institute Launches

Innovative Cardio-Oncology Program

In September of 2014 the Bon Secours Cancer Institute,

in collaboration with Dr. Gary Zeevi, launched an initiative to

establish a cardio-oncology program for patients at high risk

for heart damage due to specific chemotherapeutic

agents. This topic is an important one in regard to the long

term health and survivorship of cancer patients.

Cardiovascular Business recently published an

article exploring the emerging field of cardio-oncology,

which developed from the apparent relationship between

cancer treatment and cardiomyopathy. Cardiologists and

oncologists alike are creating protocols to screen cancer

survivors for developing heart problems—and some are

even pursuing multidisciplinary collaborations to care for the

diseases. Though few guidelines currently exist, the

European Association of Cardiovascular Imaging and the

American Society of Echocardiography recently released a

joint consensus statement on imaging for identification and

monitoring of cardiovascular complications after radiation

therapy. The Journal of the American College of

Cardiology also recently published an article offering

recommendations for the treatment of atrial fibrillation in

cancer patients. Clearly, enhanced collaboration between

cardiology and oncology has the potential to improve care

for these high-risk (and potentially high-cost) patients by

catching cardiomyopathy before it becomes debilitating.

The Cardio-Oncology Work group members include Drs.

Sherry Fox, William (Bill) Irvin, Stephen Duffy, Timothy

Wallace, Gary Zeevi, Christine Browning, pharmacists Patrick

Powell and Joy Snow, and Imaging Administrative Director,

Alan Bailey. The group is meeting monthly to

establish protocols and procedures for appropriate patient

referrals and to address the need for upgraded imaging

equipment and technical training.

If you are interested in this important topic and the

related best practices, please consider reading the

following:

1.“Cardiotoxicity of chemotherapeutic agents and

radiotherapy-related heart disease: ESMO Clinical Practice

Guidelines.” D. Boveli et al.

2. “Prevention and Treatment of Cardiomyopathy and Heart

Failure in Patients Receiving Cancer Chemotherapy.”

D. Cardinale et al.

3. “Prevention of High-Dose Chemotherapy-Induced

Cardiotoxicity in High-Risk Patients by Angiotensin-

Converting Enzyme Inhibition.” D. Cardinale et al.

4. “Reversibility of Effectively Treated Chemotherapy-

Related Heart Failure: Raising Our Awareness and a Call to

Action for Cardiology” D. Lenihan; Journal of Cardiac

Failure Vol. 20 No. 3 2014

Winter 2015

news Bon Secours Cancer Institute

Beginning Jan. 1, 2015, the cardio-oncology program

is officially open. To make referrals, call Dr. Zeevi’s

office at (804) 287-3550.

WE SEE CANCER

DIFFERENTLY

Mission The Mission of Bon Secours Health System

is to bring compassion

to health care and to be good help to those in need,

especially those who are poor and dying.

As a System of caregivers,

we commit ourselves to help bring people and communities

to health and wholeness as part of the healing ministry

of Jesus Christ and the Catholic Church.

Values Respect: Fostering courtesy, communication and trust

Justice: Supporting confidentiality, non-discrimination, human rights and advocacy

Quality: Continuously improving service, evaluating performance and exceeding our customer's standards

Integrity: Speaking the truth, fulfilling commitments and acting in accordance with our values.

Compassion: Offering care, concern, sensitivity and support.

Stewardship: Promoting resourcefulness and supporting community needs.

Innovation: Encouraging new ideas, creatively developing new services and methods of delivery.

Growth: Expanding services, supporting change and promoting staff development.

Vision Inspired by the healing ministry of the Jesus Christ and the Charisma of Bon Secours...

As a prophetic Catholic health ministry, we will partner with our communities to create a more humane world,

build health and social justice for all, and provide exceptional value for those we serve.

Bon Secours Cancer Institute News

Published by The Bon Secours Cancer Institute

5875 Bremo Rd, Suite 108

Richmond, VA 23226

(804) 287-7809

Sherry W. Fox

Vice President

Editor

Judy Heilman

Director of Marketing

Assistant Editor

Lauralee McFarland

Project Coordinator

Editorial Assistant

Design

For additional copies of this publication

please call 804-287-7508 or email

lauralee_mcfarland@bshsi.org

Contributors James “Jim” Pellicane, MD, FACS is a fellow of the American

College of Surgeons and is an active member of The American

Society of Breast Surgeons. He founded Virginia Breast Center,

the only full-service breast center in Richmond, in 2005 with his

partner, Dr. Polly Stephens. Dr. Pellicane is the Director of

Breast Oncology at the Bon Secours Cancer Institute.

William “Billy” Irvin, Jr., MD joined The Bon Secours Cancer

Institute from faculty at the University of North Carolina where he

led a nationally recognized clinical trial on pharmacogenetic

dosing of tamoxifen. His research interests include overcoming

endocrine resistance in breast cancer, triple-negative breast

cancer, and breast cancer in young women. Dr. Irvin is board

certified by the American Board of Internal Medicine and is also

board certified in medical oncology and hematology. Dr. Irvin is

the Director of Clinical Trials at the Bon Secours Cancer Institute.

news

Welcome Bon Secours Cancer Institute welcomes Dr. Michael S. Steinberg National Cancer Institute Awards Funds For Clinical Trials Bon Secours Cancer Institute receives grant to fund clinical trials. Clinical Trials Update Dr. William Irvin, Jr. and his clinical research team’s progress on current open clinical trials. Precision Cancer Care Highlights on the Bon Secours Cancer Institute’s 1st Inaugural Clinical Cancer Summit. 2nd Annual Drumheller Lecture This year’s lecture focused on pancreatic cancer awareness. Cullather Center Gives Care To Caregivers Cullather Brain Tumor Quality of Life Center hosts event for the caregivers of brain tumor patients. Short Pump Offers Support For The Girls Short Pump Town Center partners on Support Your Girls event to raise funds for the Cancer Care Fund. A Survivorship Journey Highlights on the 3rd Annual Cancer Survivorship Journey. Mask Required Highlights on the 8th Annual Pink Tie Gala sponsored by Bon Secours Cancer Institute.

features

COVER: Bon Secours Cancer Institute Launches Innovative Cardio-Oncology Program New Cardio-Oncology Program to launch beginning of the year. Virginia Breast Center Gets New FDA Approved Margin Probe for Breast Cancer Surgery Dr. Jim Pellicane talks about the new margin probe tool that will be used to assist in breast cancer surgeries. Thoracic Navigation System Comes to St. Mary’s Hospital The new Veran SPiNview Navigation System assists in thoracic surgeries. De Paul Medical Center Gets New Cancer Institute Dr. Bradley Prestidge discusses the launch of the new Cancer Institute. GE Breast Tomosynthesis Comes to Watkins and Memorial Regional Medical Center 3-D breast mammography offers a whole new way of seeing.

4 12

13

winter 2015

15 WE SEE CANCER DIFFERENTLY

4

CONTENTS Bon Secours Cancer Institute

departments

5

6

8

9

11

12

13

14

15

10

16

17

4 WE SEE

CANCER DIFFERENTLY

Virginia Breast Center Acquires New FDA

Approved Margin Probe for Breast Surgery By Dr. Jim Pellicane

INNOVATION

In breast cancer therapy, we continue to push the

envelope to do less and less in all aspects of care, from

surgery to radiation to chemotherapy, minimizing over-

treatment while still giving patients the best chance of a

cure. Lumpectomy has been the mainstay of breast

conservation surgery, but one of its pitfalls has been margin

status; that is, the amount of normal breast tissue that

surrounds the cancer after removal of the breast mass.

Margins are one the most controversial topics in breast

cancer surgery and there is no clear consensus on the

correct width of the margin, but one thing we all agree

upon is that the margin needs to be negative; that is, no

tumor at the edge of the lumpectomy specimen.

Until now there has been no good way to assess these

margins intraoperatively. Across the country positive margin

rates, with subsequent re-excision, are as high as 40%. Here

at Bon Secours Virginia Breast Center our positive margin

rates are much lower, but re-excisions remain a

problem. They are inconvenient for the patient and cost

money. We have been able to secure, at St. Francis,

St. Mary’s and Memorial Regional Medical Center, a new

FDA approved device called Margin Probe. This device uses

Radio Frequency Spectroscopy to tell the difference

between normal cells and cancer cells. When assessing

lumpectomies in the OR, the surgeon can know if the

margin is positive or negative, giving us the opportunity to

re-excise that margin while the patient is still asleep and

avoid a second operation. This device has been shown to

reduce positive margin rates by 50% no matter how low the

positive margin rate is to begin with. This saves money,

which in this day of health care reform is becoming more

and more crucial; but more importantly, will save our

patients from needing re-operative surgery, again putting

Bon Secours on the cutting edge of cancer care.

WE SEE CANCER DIFFERENTLY

5

INNOVATION

Thoracic

Navigation

System Comes

To St. Mary’s

Hospital

Bon Secours St. Mary’s Hospital announces the

acquisition of The Veran SPiNView Thoracic Navigation

System for the early detection of lung cancer. This new

technology includes a streamlined procedure flow called

SPiNPerc. St. Mary’s is the only hospital in the region to offer

this hybrid lung diagnostic procedure. Lung specialists at

St. Mary’s can now stage and attempt biopsy with a

navigated bronchoscope; and if necessary, transition to

a navigated percutaneous approach in the same

procedure. Previous to the acquisition of the Veran

SPiNView Thoracic Navigation System, patients often

experienced multiple visits to the hospital, more time off

work and potentially higher out-of-pocket costs. SPiNPerc

allows physicians to detect cancer earlier, reduce patient

anxiety and begin treatment quicker.

The Veran SPiNView Thoracic Navigation System helps

physicians reach small peripheral nodules deep in the

lungs. Small suspicious lesions in the past were difficult to

reach and often patients were left without a diagnosis.

St. Mary’s Hospital is committed to incorporating the latest

technology into its cancer program, providing the best

experience and outcomes for our patients. We believe

combining state-of-the-art technology and world-class

physicians is the right formula for the best patient care.

Lung cancer is the number one cause of cancer-

related deaths and kills more people every year than

breast, prostate, colon and pancreatic cancer combined.

Lung cancer rarely has symptoms in early stages, so

finding it early hoccurs most often when a patient has a

chest X-ray or computed tomography (CT) scan for some

other reason, and a spot is detected. A CT image is the

most common method used to detect lung

cancer. A physician’s order with the appropriate

diagnostic criteria (symptoms and medical history) is

required before a diagnostic center can use radiation

on a patient to obtain an image. People between the

ages of 55 and 80 with a 30-year smoking history of

a pack a day, are candidates for lung cancer screenings.

Lung cancer is the number

one cause of cancer-related

deaths and kills more

people every year than

breast, prostate, colon and

pancreatic cancer

combined.

WE SEE CANCER

DIFFERENTLY 6

DePaul Medical Center Launches

New Cancer Institute

NEWS

Leaders with Bon Secours Cancer Institute are

pleased to announce that the first patient in the Radiation

Therapy Center began treatment on December 15. The

Bon Secours Cancer Institute at DePaul is the next step in

Bon Secours’ effort to address the fact that, during the

2007 to 2011 data collection period by the Virginia Cancer

Registry, Chesapeake, Hampton, Norfolk, Peninsula,

Portsmouth and Western Tidewater health districts had

cancer incidence rates and mortality rates greater than

the Virginia average.

“Bon Secours has made a substantial investment

in providing a facility for the world-renowned cancer

specialists we have at Bon Secours DePaul to bring

innovative cancer treatments to the Hampton Roads

region,” said John Barrett, CEO, Bon Secours DePaul

Medical Center. “Local residents with cancer no longer

need to travel outside of Hampton Roads for cancer

treatments found only in a handful of cancer centers in

the world.”

The Bon Secours Cancer Institute at DePaul was

designed for physician collaboration and patient ease,

and features treatment spaces that maximize

convenience and efficiency for patients and families as

well as for the physicians, nurses and health care providers.

The first floor includes a multimillion dollar radiation therapy

center with a state-of-the-art TrueBeamTM STx linear

accelerator with radiosurgery capabilities, a CT simulator

for radiation therapy treatment planning, the

brachytherapy center, an outpatient pharmacy and

coming in spring 2015, an outpatient infusion center that

provides chemotherapy.

7 WE SEE CANCER DIFFERENTLY

NEWS

“With this new center, we can offer many of

today’s advanced cancer treatments, such as high-dose-

rate brachytherapy and stereotactic radiosurgery (SRS),”

said Bradley Prestidge, M.D., M.S., radiation oncologist and

regional medical director for radiation oncology with

Bon Secours Cancer Institute. “These innovations in cancer

are a real-game changer that will enable us to treat even

the most challenging cases, such as brain, pancreas and

liver cancer, with unprecedented speed and precision.”

“Our vision for this center is to offer patients a

multidisciplinary team of experts who deliver personalized

treatment plans,” said Dr. Prestidge. “Using best practices

in cancer treatment, our team will work closely with patients

and their families to develop a treatment pathway, taking

into consideration multiple options to therapy. In addition,

with this new facility we can now actively recruit more world

-renowned surgical, medical and radiation oncology

experts offering the latest treatments for fighting cancer.”

The Cancer Institute at DePaul has had a large

philanthropic component. While the fundraising effort

continues, major gift supporters to date include the Christian

Broadcasting Network; Patricia & Douglas Perry Foundation;

TowneBank Foundation; Stephen B. Ballard; Capital

Concrete, Inc., Helen Whittemore; Edward S. Garcia;

Newtown Building Supplies, Inc.; Lend Lease, William and

Marilyn Shepherd, Jr.; John Finguerra; Bank of America,

The Pink Ride, Inc., employees of Bon Secours DePaul

Medical Center and George Stenke.

Nurse navigators and oncology nurses will provide

personalized education, support and referrals to community

services and support groups. Some of the state-of-the-art

technologies used to treat and diagnose cancer that will

be available in the new facility include:

Linear Accelerator: Bon Secours has invested in a Varian

TrueBeamTM STx unit with radiosurgery capabilities. This is an

external beam radiation therapy (EBRT) unit that rotates

around the patient to deliver the prescribed radiation from

nearly any angle. The accelerator weighs more than

18,000 pounds and delivers precision radiotherapy to

cancer patients with regard to dosage and positioning,

and also offers faster treatment times.

Intensity-Modulated Radiation Therapy (IMRT): IMRT is

powerful, real-time radiotherapy that uses varying intensity

to target and deliver radiation. This capability brings new

hope to patients with the most complex cancers, including

lung, liver, abdomen, head and neck, and breast cancers.

RapidArc™: RapidArc™ radiotherapy technology is a form

of image-guided, intensity-modulated radiation therapy

(IMRT). Image guidance improves tumor targeting, and IMRT

shapes the radiation dose so that it conforms closely to the

three-dimensional shape of the tumor. This means more

dose to the tumor, and less to surrounding healthy tissue.

Stereotactic radiosurgery (SRS): SRS was initially developed

to treat small brain tumors and other conditions of the brain

with sub-millimeter accuracy. This nonsurgical procedure

delivers very high doses of precisely targeted radiation.

The result: fewer treatments for patients as compared to

traditional radiation therapy, and less damage to

surrounding tissue. The principles of SRS are now being used

to treat tumors in other parts of the body through a

procedure called stereotactic body radiotherapy (SBRT).

High-dose-rate (HDR) brachytherapy: HDR brachytherapy is

an advanced high-dose-rate radiation treatment with

pinpoint accuracy. With this therapy, a radioactive source is

placed in or near the tumor, giving it a high dose of

radiation while reducing the time needed for treatment

and reducing effects on surrounding healthy tissue.

Low-dose-rate (LDR) brachytherapy: LDR brachytherapy is a

fast, efficient type of internal radiation therapy that delivers

low doses of radiation through implants that are placed

close to a tumor. With LDR, radioactive “seeds” are sent to

the tumor through tiny catheters, delivering a continuous

dose of radiation over a course of one to seven days −

instead of the nearly nine weeks required for some types of

radiation treatments.

“Our vision for this center is to

offer patients a multidisciplinary

team of experts who deliver

personalized treatment plans.”

-Dr. Bradley Prestidge.

Left, Mayor Paul Fraim, City of Norfolk and right, Bradley Prestidge, MD, MS, regional medical director for Bon Secours Radiation Oncology Services

8 WE SEE

CANCER DIFFERENTLY

NEWS

Digital breast tomosynthesis, or 3-D mammography,

allows radiologists to examine breast tissue one layer

at a time to inspect for any abnormalities in the tissue.

During a 3-D mammogram, multiple images of the

breast are acquired at different angles. Using high-

powered computing, digital breast images are then

converted into a stack of very thin layers, or “slices”.

These images can be viewed as a detail 3-D

reconstruction of the breast.

3-D mammography, when combined with convention

2-D mammography, has a 40 percent higher detection

rate of Invasive cancer than conventional 2-D

mammography alone, thereby helping doctors

diagnose cancer at an earlier stage.

3-D mammography also reduces the number of false

positives and callbacks to get second images. These

callbacks often cause unnecessary anxiety because,

many times, no cancer is found in the second images.

Memorial Regional Medical Center and Watkins Centre have recently acquired the technology to start 3-D mammography

in the middle of February. Doctors and scientists agree that early detection is the best defense against breast cancer.

Successful treatment and survival rates for breast cancer patients are dramatically affected by early detection of

breast cancers.

Memorial Regional Medical Center

& Watkins Centre Offer A Whole

New Way Of Seeing With

GE Breast Tomosynthesis

Patients with one or more of the following conditions or

criteria should consult with a physician to schedule an

exam:

Have a serious breast problem, such as swelling

of all or part of a breast, even if no distinct

lump is felt; skin irritation or dimpling; breast or

nipple pain; nipple retraction; redness, scaliness

or thickening of the nipple or breast skin; nipple

discharge other than breast milk.

Are under the age of 35.

Have a personal history of breast cancer.

Are back for your first mammogram after having

breast surgery for any abnormal condition.

Are having a follow-up mammogram

less than 12 months from your most recent

normal mammogram.

Because many insurance companies are not yet

covering this technology, patients may have a $50 fee

for 3-D mammography.

To schedule a mammogram please, call 804-627-5660.

congratulations

Donna Moore Wilson, RN, BSN,CBCN, nurse navigator at Bon Secours Cancer Institute at St. Mary’s Hospital,

was selected as Oncology Nurse of the year at the March of Dimes Nurse of the Year award’s ceremony.

In addition to her daily work with cancer patients, compassionately guiding and advising them, she spends

countless hours of her own time performing community outreach on behalf of Bon Secours and cancer

patients. Per Pat Gavilan, Manager of Diversity and Cross Cultural Services, “Donna works closely with our

office to make sure the needs of the non-English speaking patients are being met. Her compassion and

sensitivity are admirable! She always goes above and beyond.” Congratulations, Donna.

Sherry Fox, RN, PhD, Vice President of Bon Secours Cancer Institute and Director of Cullather

Quality of Life Brain Tumor Center, received the American Cancer Society Lane Adams Quality of Life Award

which promotes improved quality of life for all persons with cancer and their families through public

recognition of exemplary individuals who practice compassionate, skilled cancer care and who extend the

warm hand of service. Thank you, Dr. Sherry Fox, for your dedicated service.

WE SEE CANCER DIFFERENTLY 9

WELCOME/RECOGNITION

Dr. Steinberg attended City College of New York for his

undergraduate training and graduated with a BS with a major

in Chemistry. He received his medical degree from New York

University and a PhD in Pharmacology from NYU Graduate

School. He completed a medical internship and residency and

part of his Hematology Fellowship at Bellevue Hospital/NYU. He

then served in the United States Army Medical Corps and was

stationed at the Walter Reed Army Institute of Research and

completed his Hematology Fellowship at the Walter Reed Army

Medical Center. He then completed a Medical Oncology

Fellowship at the Memorial Sloan Kettering Cancer Center in

New York. Dr. Steinberg is certified in Internal Medicine,

Hematology and Medical Oncology by the American Board of

Internal Medicine.

Meet the Physician: Bon Secours Cancer Institute

Welcomes

Michael S. Steinberg, MD Hematology/Oncology

Rappahannock General Hospital

Michael S. Steinburg, MD

michael_steinberg@bshsi.org

Phone: 804-435-8583

Fax: 804-435-8302

RESEARCH

10 WE SEE

CANCER DIFFERENTLY

Cathy Lantz, RN,MS, AOCNS Emmett “Buddy” Grubb

(patient) Sarone Salaam, LPN The Drumheller Family

The National Cancer Institute (NCI) has awarded

$93 million a year for 5 years to researchers across the

country to conduct multi-site cancer clinical trials and

cancer care delivery research studies in their

communities. The grants are awarded under the NCI

Community Oncology Research Program (NCORP),

a national network of investigators, cancer care

providers, academic institutions, and other

organizations that provide care to diverse populations

in community-based healthcare practices across the

United States.

Bon Secours Cancer Institute is participating in the

cancer clinical research through the Southeast

Clinical Oncology Research Consortium, Inc. (SCOR)

based in Winston-Salem, NC. The SCCC was a

Community Clinical Oncology Program (CCOP)

funded by NCI since 1987 providing access to cancer

clinical trials to 18 community hospitals/institutions over

a 5 state area (GA, NC, SC, TN, and VA). The SCCC

merged with Upstate Carolina CCOP located in

Spartanburg, SC to apply for the NCORP grant award.

A new organization was funded and will operate

under the name of Southeast Clinical Oncology

Research Consortium, Inc (SCOR) NCORP. The SCOR

received an award of approximately $14.8 million over

5 years and will provide access to cancer clinical

research to 23 community hospitals/institutions.

NCORP will design and conduct clinical trials to

improve cancer prevention, cancer control,

screening, and post-treatment management. The

new program will have an expanded portfolio of

clinical trials and other studies, including an emphasis

on cancer care delivery research. Cancer care

delivery research focuses on numerous factors that

affect access to medical care such as social,

financial, technological, and others. The two

institutions within SCOR that will initially be instrumental

in establishing cancer care delivery research are

Novant Health Forsyth Medical Center in Winston-

Salem, NC and Gibbs Cancer Center in Spartanburg,

SC. The other 21 member community hospitals/

institutions will participate in the cancer care delivery

research as the program advances and participation

is expanded.

National Cancer Institute Awards Grant To

Bon Secours Cancer Institute

11 WE SEE CANCER DIFFERENTLY

Mary Ann Sweeney, RN, OCN

Clinical Trials Update By William Irvin, Jr., MD

For more information on clinical

trials or to refer patients,

please contact:

Kathy Patterson

Clinical Research Coordinator

804-893-8665

katheryn_patterson@bshsi.org

Open Clinical Trials The following Bon Secours Medical Oncology clinical trials are open and enrolling patients:

BREAST CANCER

A011202 Randomized Trial Evaluating The Role Of Axillary Lymph Node Dissection In Breast Cancer Patients (Ct1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

BREAST CANCER

NSABP B-55/ BIG 6-13 A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study To Assess The Efficacy And Safety Of Olaparib Versus Placebo As Adjuvant Treatment In Patients With Germline Brca1/2 Mutations And High Risk Her2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment And Neoadjuvant Or Adjuvant Chemotherapy

BREAST CANCER

S1202 Duloxetine Hydrochloride To Treat Muscle, Bone And Joint Pain In Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy

COLORECTAL

CALGB 80702 A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant Folfox Plus Celecoxib Or Place-bo For Patients With Resected Stage III Colon Cancer

KIDNEY

S0931 Everest: Everolimus In Treating Patients With Kidney Cancer Who Have Undergone Surgery

LUNG

E5508 Randomized Phase III Study Of Maintenance Therapy With Bevacizumab, Pemetrexed Or A Combination Of Bevacizumab And Pemetrexed Following Carboplatin, Paclitaxel And Evacizumab For Advanced Non-Squamous NSCLS Randomized Phase III Study Of Maintenance Therapy With Bevacizumad, Pemetrexed Or A Combination Of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel And Evacizumab For Advanced Non-Squamous NSCLC

GI RECTAL

N1048 Phase II/III Trial Of Neoadjuvant Folfox With Selective Use Of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation For Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision

KIDNEY

E2810 Randomized, Double-Blind Phase III Study Of Pazopanib Vs. Placebo In Patients With Metastic Renal Cell Carcinoma Who Have No Evidence Of Disease Following Metastatectomy

RESEARCH

Bon Secours Cancer Institute

Inaugural Clinical Cancer Summit

Precision Cancer Care: Current Evidence & Future Direction

WE SEE CANCER

DIFFERENTLY 12

NEWS

Dr. George Knaysi was

presented the Lifetime

Achievement Award for his

incredible 40+ years of service

to the Richmond community.

Dr. George Knaysi and wife, Susan Knaysi

Howard McLeod, PharmD/ Gennady Bratslavsky, MD/ Anton J. Bilchik, MD, PhD, FACS/ David S. Schrump, MD, MBA, FACS/ Carey K. Anders, MD

The Inaugural Summit of the Bon Secours Cancer Institute

took place on Friday, October 10 in Richmond on the topic

of “Precision Cancer Care: Current Evidence and Future

Direction.” Precision Cancer Care is the new frontier in

patient-centered cancer care and promotes an evidence-

based approach to treating each cancer patient

individually.

The Summit offered a rare convergence of clinical

experts in the fields of medical, surgical and radiation

oncology who discussed a multi-disciplinary approach to

treating patients with breast, colon, lung and prostate

cancer. Bon Secours Cancer specialists led the group in

panel discussions during morning and afternoon sessions.

146 attendees from across the state, 36 of whom were

physicians, dove deeply into the topic of personalized

medicine through the presentations of 5 distinguished

cancer specialists: Dr. Howard McLeod of DeBartolo

Institute, Dr. Cary Anders from University of North Carolina,

Dr. David Schrump of National Cancer Institute, Dr. Anton

Bilchik from John Wayne Cancer Institute and Dr. Gennady

Bratslavsky of Syracuse University.

The widespread and generous sponsorship of 14 vendors

who exhibited at the conference supported free registration

for all attendees. The new Bon Secours Health Fair van was

also on site for tours.

Dr. George Knaysi was honored with the Lifetime

Achievement Award for his dedication as a breast surgeon

with heart felt remarks shared by Dr. James Pellicane,

surgeon and founder of Virginia Breast Center.

13 WE SEE CANCER DIFFERENTLY

2nd Annual Drumheller

Cancer Lecture & Dinner

Highlights Pancreatic Cancer Awareness

Kathy Drumheller Dr. TJ Wallace (left ) and Dr. Steven Duffy (right)

Cathy Lantz, RN,MS, AOCNS Robert Allen

(patient) Sarone Salaam, LPN Mary Ann Sweeney, RN, OCN The Drumheller Family

Photos by David Everette

The 2nd annual Drumheller Gastrointestinal Lecture took

place on Thursday, Nov 13 at the John Marshall

ballroom. Wendy Pestrue, Senior Development Officer for

Bon Secours Richmond Healthcare Foundation, emceed

the lecture which addressed “New Frontiers in Pancreatic

Cancers.” Gastric or stomach cancer is one of the leading

causes of death worldwide. Diagnosis is often delayed or

undetected because symptoms may not occur in the early

stages of the disease. In the United States, about 21,600

cases of stomach cancer are diagnosed annually.

Guest speakers included T. J. Wallace, MD with

Radiation Oncology Associates, Steve Duffy, MD with Bon

Secours Cancer Institute Medical Oncology at St. Mary’s

Hospital and Itzhak Avital, MD with Bon Secours Cancer

Institute Surgical Oncology. Special guests included former

patients of Dr. Avital who had been treated by the Bon

Secours Cancer Institute. Physicians and clinicians in the

field of cancer attended the event.

The Drumheller family established the Drumheller Cancer

Fund in memory of Ken Drumheller who died the day before

his 46th birthday of gastrointestinal cancer. After receiving his

diagnosis, Ken and his wife Kathy recognized the need in

the community and nation for more education, awareness

and resources to support the early detection and diagnosis

of gastric and abdominal cancers. The Ken Drumheller

Gastric Cancer Fund honors Ken’s commitment to help his

community fight cancer. For more information visit

www.bsvaf.org/drumheller

“Ken was always such a giving person. We can’t let him go without helping others.” ~Kathy Drumheller

WE SEE CANCER

DIFFERENTLY 14

Cullather Center Gives

Care to the Caregivers The Cullather Center is always searching for ways to

add new programs and activities to help our

caregivers. Charity Yanishak, the widow of Drew

Yanishak, approached us about hosting a Caregiver

Respite and Relaxation Day. After a long journey

with many ups and downs, Drew lost his battle with

brain cancer this past year. Charity often had friends

and family try to encourage her during his 6-year

journey to get away for a weekend, but she just wasn’t

comfortable leaving the stability of their home

environment. As do so many of our families who have

suffered, Charity chose to think of others and came up

with a wonderful idea! She thought, “Why don’t we

have a day filled with massage, yoga, meditation,

cooking therapy, art therapy, and salon services?

A way of just getting away from the daily stress of

caregiving, even if just for an hour or two.” So from

Charity’s generous heart came this very special day

just for our Caregivers.

We held the first Caregiver Respite/Relaxation Day

on September 26th with the assistance of the Evelyn

D. Reinhardt Guest House. Eleven people attended.

Sr. Charlotte Lange was kind enough to attend and

offer the blessing. It was a wonderful day of relaxation!

A harpist played the whole day, which just set the tone

as the participants, went about the day’s activities. As

they left, each participant was given a basket with items to

promote wellness and relaxation. We are very grateful for

Charity’s guidance and leadership on this project!

Chef Sean Murphy, from the Savory Grain, prepared a cooking

demonstration for the group.

COMMUNITY OUTREACH

Total mammograms scheduled 11

Attendees 250

Total amount raised for the Bon Secours Cancer Fund $3330

Women under the age of 40 who came to be educated on breast health and awareness 22.4%

15 WE SEE CANCER DIFFERENTLY

Short Pump Joins

Bon Secours for

“Support Your Girls” Event

COMMUNITY OUTREACH

A premiere Support Your Girls event took place at Short Pump Town Center on

Thursday, October 2. For the first time, Bon Secours supported the fight against breast

cancer by hosting our signature breast cancer awareness event at the area’s largest

outdoor mall with 250 attendees paying a $25 fee to participate. Proceeds from the

ticket sales went to the Bon Secours Richmond Healthcare Foundation’s Cancer Care

Fund. Attendees visited vendor booths hosted by Bon Secours representatives and

other companies including Virginia Breast Center, the Bon Secours Good Help

Pharmacy, Every Women’s Life, Survivorship, Patient Navigation, Planet Hair, Pink Tie

Gala, Richmond Aesthetic Surgery, and LINC. They also enjoyed wine tastings and

appetizers from participating retailers and restaurants including Kate Spade,

Nordstrom, Lehja, Oil & Vinegar, Chico’s, Cyndi Rose, Schwarzschild, Nordstrom,

Dillard’s and Maggiano’s.

The evening’s festivities commenced with a testimony from Mark Newlen, founder

of Look Better Than You Feel camisoles, whose wife, Kim, died of breast cancer last

year. Luminaries were then lit in memory or in honor of a loved one affected by

breast cancer.

16 WE SEE

CANCER DIFFERENTLY

The third annual area-wide cancer survivorship conference,

“The Survivorship Journey: Embracing Your New Normal,”

was held at Lewis Ginter Botanical Gardens on November

1st from 8:30am to 3pm. It was once again offered free to

our community’s cancer survivors and their caregivers

through the generosity of our three major medical systems in

Richmond and VA Cancer Institute, as well as 14 area

organizations and businesses. There were 155 participants in

attendance, and the presentations this year included the

emotional impact of cancer co-led by an area oncology

administrator and a breast cancer survivor, genetics and

cancer risk assessment, the financial/legal challenges of

cancer, diet and nutrition for cancer risk reduction, the role

of immunotherapy in cancer, and a physical activity session

featuring yoga, gentle exercise, and salsa.

There were over 15 area agencies and organizations

represented in our vendor area: Bon Secours Cancer

Institute, HCA Cancer Care Network, VCU Massey

Cancer Center, Abbot Nutritional Support, Stepping Stones

Women's Center, Ambry Genetics, American Cancer

Society, Legal Information Network for Cancer (LINC), the

Prostate Cancer Educational Institute of VA, Oncology

Nursing Society’s Richmond Chapter/Camp Phoenix, Senior

Connections, Hitting Cancer Below the Belt /Sisters Network

Central VA and Richmond, Komen Central VA Affiliate, VA

Breast Cancer Foundation, and the Paredes institute.

Barb Peek, RN and Becky Mains, RN—both staff nurses in the

St. Mary’s Outpatient Infusion Center--staffed the Bon

Secours Cancer Institute table, promoting the services

available to patients through our system. Mary Baker, NP

served as moderator for the day. Evaluations were very

positive with many attendees requesting that this

programming continue. They informed us that it has

impacted their health as survivors in a positive way.

The Survivorship Journey:

Embracing Your New Normal

COMMUNITY OUTREACH

WE SEE CANCER DIFFERENTLY

17

Mask Required:

Pink Tie Gala

Throws Masquerade Ball

to Raise Money for

Breast Cancer

Digital breast tomosynthesis, or 3-D mammography, al-

lows radiologists

to examine breast tissue one layer at a time to inspect for

any

abnormalities in the tissue.

-D mammography, when combined with convention-

al 2-D

mammography, has a 40 percent higher detection rate

of invasive

cancer than conventional 2-D mammography alone,

thereby helping

doctors diagnose cancer at an earlier stage.

The 9th Annual Pink Tie Gala presented by Bon Secours

Cancer Institute was, by everyone’s account, the most

spectacular and “over the top” Pink Tie event yet! This was

the Pink Tie Gala’s first “themed” event and the positive

feedback has been overwhelming.

This year’s theme was a Victorian masquerade ball and

started off with Jonathan Austin doing close up magic

shows in the foyer as the sponsors were treated to an

intimate hors d'oeuvre reception before the main event.

The doors were then opened to the gala and guests were

greeted by doormen and characters in full period

costume.

The presentations began after guests had dined and was

hosted by Kat Simons of Lite 98. They began with a Six Year

Sponsor Award to Bon Secours Cancer Institute and a

special award to Dr. James Pellicane for his work in the

breast cancer field. The evening continued with Dr. William

Irvin Jr. (symbolically representing the caring medical

professionals that are so important in battling this disease)

and his professional dance partner performing a ballroom

dance exhibition. This was then followed by this year’s

Celebration of Life Dancers, seven breast cancer survivors

(all novice dancers who have taken 12 weeks of dance

lessons donated by Rigby’s Jig Dance studio), and their

professional dance partners, each doing a choreographed

ballroom dance performance. To further add to the

evening and the guests enjoyment, a live video feed of the

performances were projected on to two giant 20 foot wide

screens one on either side of the grand ballroom.

In total, more than 600 guests attended this sold out event,

and raised funds for important breast cancer programs in

the Central Virginia area through Susan G. Komen For

the Cure.

COMMUNITY OUTREACH

18 WE SEE

CANCER DIFFERENTLY

COMMUNITY OUTREACH

Pink Pastry

Bake Sale

Raises Funds

for Breast Cancer

St. Francis Medical Center’s Medical Oncology

Hosts Lung Cancer Event

In just 3 days The Pink Pastry raised a grand total of $2324 ,

which will be split evenly between the Bon Secours Cancer

Care Fund and American Cancer Society "Making Strides

Against Breast Cancer"! The positive feedback from

everyone was a great feeling. Others were so happy to see

the all the pink "lighting up” the area! Many shared stories

about people they knew who were battling cancer. Others

spoke about their own experiences. There were also a lot of

survivors just wanting to give back. Some people did not

even buy anything but just wanted to donate. One woman

wrote a check for $300 dollars-truly amazing! These were

3 amazing days of giving back. Big thanks to Health Partners

Lab and to local community bakers and bake shops Cakes

by Grahams, Shingdigz, Sugar Fix Bakery, Arygle Cupcakes,

Libby Market, Fresh Market and Southern Seasons for

donating baked goods.

Tina Burch, practice supervisor for St. Francis Medical

Center Medical Oncology, took the lead and brought this

great program to our community. Patients and families en-

joyed a time of information, testimonials and

celebration. Dr. Lockhart spoke about the interdisciplinary

approach we take with our patients and Dr. Raddin spoke

about lung cancer screening. We then had a time of

sharing and testimonials from many of our patients.

We had a great turnout for this first time event!

Shine a Light on Lung Cancer provides our amazing

community with hope, inspiration and support for those

impacted by lung cancer and those at risk—from survivors to

the newly diagnosed to loved ones to healthcare

professionals to those simply wanting to help. You will learn

about the latest advancements for lung cancer, hear

stories of survival and will be connected with others in the

lung cancer community.

Here is the website and more information about the Shine

the Light program: http://

shinealightonlungcancer.kintera.org/faf/home/default.asp?

ievent=1125049

letter

to the

editor Sherry Fox–

I have read the entire Fall 2014 newsletter – it is

overwhelming the amount of activity that is

underway now. The research grants and clinical

studies are impressive, and a new chapter in the

history of Bon Secours Richmond. We have

entered a new era, with a Cancer Program that

will soon be recognized widely! Thanks to you

for your effort pulling it all together to showcase

for all to see and know.

Charles Welander, MD

WE SEE CANCER DIFFERENTLY 19

UPCOMING CANCER

AWARENESS MONTHS

January

CERVICAL CANCER

February

NATIONAL CANCER

PREVENTION

GALL BLADDER &

BILE DUCT CANCER

March

COLORECTAL CANCER

KIDNEY CANCER

Bon Secours Cancer Institute

2nd Annual Clinical Cancer Summit

October 1 & 2, 2015

DoubleTree by Hilton Hotel Williamsburg, Virginia

Digital breast tomosynthesis, or 3-D mammography, al-

lows radiologists

to examine breast tissue one layer at a time to inspect for

any

abnormalities in the tissue.

-D mammography, when combined with convention-

al 2-D

mammography, has a 40 percent higher detection rate

of invasive

cancer than conventional 2-D mammography alone,

thereby helping

doctors diagnose cancer at an earlier stage.

SAVE THE DATE!

St. Francis Medical Center

Richmond Community Hospital

Watkins Center

Memorial Regional Medical

Cancer Institute at Reynolds Crossing Cancer Institute at St. Francis

St. Mary’s Hospital

The Bon Secours Cancer e-newsletter is published by Judy Heilman and Sherry Fox.

Contact Judy Heilman at 281-8367 or judy_heilman@bshsi.org for submissions, suggestions, calendar events, etc.